Biotech Values

[DewDiligence]

>> Even #2, assuming a need for a 2nd and larger pivotal trial and multi year delay would be considered a negative outcome. >>

As mentioned in the previous post, I think it’s already highly likely that the phase-2b won’t be eligible for consideration as a pivotal.